AgomAb Therapeutics, a Belgium-based Phase 2 biotech focused on immunology and inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. The company's initial focus is on chronic fibrotic indications with high unmet medical need, through inhibition of one of the key signaling pathways involved in fibrosis, the transforming growth factor ß, or TGFß, pathway. AgomAb Therapeutics' lead product candidate, ontunisertib (AGMB-129), is a selective and potent oral, gastrointestinal-restricted small molecule inhibitor of ALK5, or TGFßR1, in development for the treatment of Fibrostenosing Crohn’s Disease, or FSCD. AGMB-447, its second clinical-stage product candidate, is an inhaled small molecule inhibitor of ALK5, or TGFßR1, in development for the treatment of idiopathic pulmonary fibrosis, or IPF.
The Antwerp, Belgium-based company was founded in 2017 and plans to list on the Nasdaq under the symbol AGMB. AgomAb Therapeutics filed confidentially on June 20, 2024. J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are the joint bookrunners on the deal. No pricing terms were disclosed.
